Stocks Slip as Pand...
Health Care: Drugs
Neostem Inc. (NBS: AMEX)
$0.59 0.02 | 3.51%
05/24/13 - 03:59 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 0.59 |
| 52 Week High | 0.84 |
| 52 Week Low | 0.38 |
| Avg. Daily Vol. (Mil) | 1.10 |
| Beta (3 year) | 1.42 |
| Share Related Items | |
| Mkt Cap (Mil) | 114.34 |
| Shares Out (Mil) | 193.80 |
| Float (Mil) | 137.34 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 1.10 |
| Current Ratio | 1.40 |
| LT Debt/ Equity | 0.01 |
| Total Debt / Equity | 0.01 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 8.74 |
| Price/Book | 3.89 |
| Price/Cash Flow | -1.70 |
| Per Share Data | |
| Earnings | -0.36 |
| Sales | 0.07 |
| Book Value | 0.15 |
| Cash Flow | -0.34 |
| Business Summary | |
|---|---|
| Neostem, Inc., is an international biopharmaceutical company. It operates in three reportable segments namely Cell Therapy-United States; Regenerative Medicine-China; and Pharmaceutical Manufacturing-Manufacturing. | |
| General Information | |
| 420 Lexington Avenue
Suite 350 New York, NY 10170 |
|
| www.neostem.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 97 | |
| CEO: Dr. Robin L. Smith | |
| Short Interest | |
| Current Month (Mil) | 4.75 |
| Previous Month (Mil) | 5.05 |
| Short Interest Ratio (Days) | 3.60 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -132.30 |
| Return on Investments | -223.00 |
| Profitability | |
| Gross Margin | 21.20 |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with NBS
- Portfolio NameUser Type
- Usermine
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- UserChris
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
Latest NBS Headlines from TheStreet
- NeoStem Announces Geographic Expansion Of Intellectual Property Coverage Of Cardiovascular Asset AMR-001 05.16.13 | 07:05 am
- NeoStem To Present At Multiple Conferences In May 05.14.13 | 07:05 am
- NeoStem's Subsidiary, Progenitor Cell Therapy, To Provide Autologous And Allogeneic Cellular Therapy Services To MedStar Georgetown University Hospital 05.13.13 | 07:05 am
- NeoStem Clarification: No New Securities Being Issued 05.09.13 | 07:05 pm
- NeoStem CEO's Letter To Shareholders 05.09.13 | 04:05 pm
- NeoStem Announces Closing Of Public Offering Of Common Stock 05.03.13 | 08:05 am
- NeoStem Announces Partial Exercise Of Underwriters' Over-Allotment Option 04.30.13 | 06:04 pm
- NeoStem Announces Pricing Of Public Offering Of Common Stock 04.29.13 | 08:04 pm
- NeoStem Announces Proposed Public Offering Of Common Stock 04.29.13 | 04:04 pm
- NeoStem's Subsidiary, Progenitor Cell Therapy, Enters Into A Services Agreement With Sentien Biotechnologies, Inc. 04.29.13 | 08:04 am
Press Releases for NBS
- Faruqi & Faruqi, LLP Launches Investigation Against NeoStem, Inc. (NBS) For Potential Breaches Of Fiduciary Duties By Its Board Of Directors In The Manner It Seeks Executive Compensation Approval - Business Wire 09.18.12 | 04:09 pm
- Donald Trump, Jr. Headlines As Special Speaker At The WallStreet Research⢠Small Cap Conference VII, Being Held At The Penn Club (Affiliated With The Wharton School Of Finance) On November 15th - PR Newswire 11.15.11 | 07:11 am
- NeoStem Acquires Amorcyte, A Clinical Stage Cardiovascular Disease Cell Therapy Company - PR Newswire 10.17.11 | 09:10 am
- NeoStem Announces Participation In Multiple October Conferences - PR Newswire 10.04.11 | 08:10 am
- NeoStem's Subsidiary, Progenitor Cell Therapy, And ImmunoCellular Therapeutics Enter Into A Manufacturing Agreement - PR Newswire 10.03.11 | 08:10 am
- NeoStem Announces Participation In Multiple September Conferences - PR Newswire 09.08.11 | 05:09 pm
- NeoStem Announces The Receipt Of Over $1,700,000 In DOD Funding For Its VSEL⢠Technology Being Developed To Treat Osteoporosis - PR Newswire 08.08.11 | 09:08 am
- NeoStem Subsidiary, Progenitor Cell Therapy, Announces Extension Of Manufacturing Agreements With Two Existing Clients - PR Newswire 07.18.11 | 09:07 am
- NeoStem Announces The Addition Of Joseph Talamo As Vice President, Corporate Controller And Chief Accounting Officer - PR Newswire 06.30.11 | 09:06 am
- The Pontifical Council For Culture And NeoStem Announce Steps Forward In Their Partnership To Advance Adult Stem Cell Research - PR Newswire 06.16.11 | 07:06 am
Partner Headlines for NBS
- Gain An Innovation, Strategic Edge With Partnerships - Investor's Business Daily 04.09.13 | 02:04 pm
- Cell Therapy Leader Stephen Potter Talks Osiris, NeoStem And The Industry Itself - Seeking Alpha 03.19.13 | 09:03 am
- 3 Regenerative Medicine Companies That Could Deliver In 2013 - Seeking Alpha 01.22.13 | 09:01 am
- Neuralstem Swinging For The ALS Fences - Seeking Alpha 10.29.12 | 09:10 am
- Forex Flash: Sheding some light on China/HSBC PMI differences - Markit - NASDAQ 09.03.12 | 12:09 am
- Cell Therapy Outlook Starting To Match Clinical Results - Seeking Alpha 08.21.12 | 09:08 am
- Reassessing & Continuing To Monitor Portfolios For Success - Seeking Alpha 07.30.12 | 09:07 am
- Baxter And Neostem Validating Each Other's Cell Therapies - Seeking Alpha 06.01.12 | 09:06 am
- Rodman & Renshaw Reiterates NeoStem Market Outperform, $3 PT - Benzinga 07.20.11 | 01:07 pm
- Morning Market Losers - Benzinga 07.19.11 | 09:07 am
